Sinclair Pharma PLC Hardman Research: Poised for a long term uplift
November 08 2016 - 3:08AM
RNS Non-Regulatory
TIDMSPH
Sinclair Pharma PLC
08 November 2016
Hardman Research: Poised for a long term uplift
Poised for a long term uplift: Sinclair has evolved into a
pure-play aesthetics company with a concentrated and highly
competitive portfolio of differentiated injectable aesthetics
products. These products target unmet clinical needs for effective,
high quality, longer duration, natural looking and
minimally-invasive treatments, which is a significant growth
opportunity. Sinclair has an established sales and marketing
presence in Europe, direct sales in Brazil, and operates through an
international group of distributors in other markets, including SE
Asia and the US. With the benefit of a strong balance sheet,
Sinclair is investing in an accelerated growth phase and margin
expansion.
Please click here for the full report:
http://www.hardmanandco.com/docs/default-source/company-docs/sinclair-pharma-plc-documents/08.11.16-poised-for-a-long-term-uplift.pdf
To contact us: Contact: Dr Martin Hall
Hardman & Co mh@hardmanandco.com
11/12 Tokenhouse Paul Singer
Yard ps@hardmanandco.com
London Telephone: +44 20 7929 3399
EC2R 7AS Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGIBDBISGBGLI
(END) Dow Jones Newswires
November 08, 2016 04:08 ET (09:08 GMT)
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From Apr 2024 to May 2024
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From May 2023 to May 2024